GlassScriptPhysician profile
Nagapratap Ganta
NPI 1134757883
$1,409.29
in general payments reported to CMS, 2019-2025
14 companies · $754 in 2025
The $754 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.90 · 2024: $639 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083 · Education: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.32 |
| Education | $325.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $238.21 | 2024-2025 | Jakafi |
| Astellas Pharma US INC | $230.97 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $144.06 | 2025 | Calquence |
| Pharmacosmos Therapeutics INC. | $124.97 | 2025 | Cosela |
| Taiho Oncology, INC. | $115.27 | 2024 | |
| Intera Oncology, INC | $115.02 | 2024 | Intera |
| Genmab U.S., INC. | $110.18 | 2024 | Epkinly |
| Lilly USA, LLC | $104.59 | 2025 | Verzenio |
| Janssen Biotech, INC. | $71.18 | 2025 | Carvykti, Tecvayli, Darzalex |
| Glaxosmithkline, LLC. | $64.16 | 2024 | Ojjaara |
| Abbvie INC. | $40.75 | 2025 | Imbruvica, Epkinly |
| Servier Pharmaceuticals LLC | $18.94 | 2025 | Tibsovo |
| Apellis Pharmaceuticals, INC. | $16.90 | 2023 | Empaveli |
| Janssen Pharmaceuticals, INC | $14.09 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagapratap Ganta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.